Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
Back to Home

Insmed Incorporated

NASDAQ: INSM $122.83 USD~$13B MCAP

Commercial-stage biopharmaceutical company developing therapies for rare and serious diseases, including ARIKAYCE for refractory NTM lung infection and brensocatib for bronchiectasis.

Company Info

Sector:Biotechnology
Headquarters:Bridgewater, New Jersey, USA
Founded:1999
Website:insmed.com/

Upcoming Milestones & Key Dates

Late 2026
PDUFA

Brensocatib FDA decision (bronchiectasis)

2027 H1
Clinical Readout

TPIP Phase 3 long-term data

Clinical Development Pipeline

ARIKAYCE (amikacin liposome inhalation suspension)

Target: Amikacin
Refractory NTM lung infection
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Brensocatib

Target: DPP1
Bronchiectasis
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Treprostinil palmitil (TPIP)

Target: Prostacyclin
Pulmonary arterial hypertension (PAH)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Clinical RegulatoryPR Newswire FDA

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE

The FDA granted priority review to Insmed's supplemental NDA for ARIKAYCE (amikacin liposome inhalation suspension) for the treatment of MAC lung disease, with a PDUFA target action date set for January 28, 2027.

Leadership Team

Will Lewis

Chair and Chief Executive Officer

Sara Bonstein

Chief Financial Officer

Chief Medical Officer

Head of Clinical Development

Careers & Job Openings

Associate Director, Regulatory Affairs Project Manager

Regulatory Affairs
Bridgewater, NJ
Apply Now

Therapeutic Specialist, Salt Lake City

Sales
Working from Home
Apply Now

Manager, DSPV Pharmacovigilance Agreements

Pharmacovigilance
Working from Home
Apply Now